Literature DB >> 22525418

TNM staging of neoplasms of the endocrine pancreas: results from a large international cohort study.

G Rindi1, M Falconi, C Klersy, L Albarello, L Boninsegna, M W Buchler, C Capella, M Caplin, A Couvelard, C Doglioni, G Delle Fave, L Fischer, G Fusai, W W de Herder, H Jann, P Komminoth, R R de Krijger, S La Rosa, T V Luong, U Pape, A Perren, P Ruszniewski, A Scarpa, A Schmitt, E Solcia, B Wiedenmann.   

Abstract

BACKGROUND: Both the European Neuroendocrine Tumor Society (ENETS) and the International Union for Cancer Control/American Joint Cancer Committee/World Health Organization (UICC/AJCC/WHO) have proposed TNM staging systems for pancreatic neuroendocrine neoplasms. This study aims to identify the most accurate and useful TNM system for pancreatic neuroendocrine neoplasms.
METHODS: The study included 1072 patients who had undergone previous surgery for their cancer and for which at least 2 years of follow-up from 1990 to 2007 was available. Data on 28 variables were collected, and the performance of the two TNM staging systems was compared by Cox regression analysis and multivariable analyses. All statistical tests were two-sided.
RESULTS: Differences in distribution of sex and age were observed for the ENETS TNM staging system. At Cox regression analysis, only the ENETS TNM staging system perfectly allocated patients into four statistically significantly different and equally populated risk groups (with stage I as the reference; stage II hazard ratio [HR] of death = 16.23, 95% confidence interval [CI] = 2.14 to 123, P = .007; stage III HR of death = 51.81, 95% CI = 7.11 to 377, P < .001; and stage IV HR of death = 160, 95% CI = 22.30 to 1143, P < .001). However, the UICC/AJCC/WHO 2010 TNM staging system compressed the disease into three differently populated classes, with most patients in stage I, and with the patients being equally distributed into stages II-III (statistically similar) and IV (with stage I as the reference; stage II HR of death = 9.57, 95% CI = 4.62 to 19.88, P < .001; stage III HR of death = 9.32, 95% CI = 3.69 to 23.53, P = .94; and stage IV HR of death = 30.84, 95% CI = 15.62 to 60.87, P < .001). Multivariable modeling indicated curative surgery, TNM staging, and grading were effective predictors of death, and grading was the second most effective independent predictor of survival in the absence of staging information. Though both TNM staging systems were independent predictors of survival, the UICC/AJCC/WHO 2010 TNM stages showed very large 95% confidence intervals for each stage, indicating an inaccurate predictive ability.
CONCLUSION: Our data suggest the ENETS TNM staging system is superior to the UICC/AJCC/WHO 2010 TNM staging system and supports its use in clinical practice.

Entities:  

Mesh:

Year:  2012        PMID: 22525418     DOI: 10.1093/jnci/djs208

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  131 in total

1.  Long-term outcomes and prognostic factors in 78 Japanese patients with advanced pancreatic neuroendocrine neoplasms: a single-center retrospective study.

Authors:  Lingaku Lee; Hisato Igarashi; Nao Fujimori; Masayuki Hijioka; Ken Kawabe; Yoshinao Oda; Robert T Jensen; Tetsuhide Ito
Journal:  Jpn J Clin Oncol       Date:  2015-09-15       Impact factor: 3.019

Review 2.  Pancreatic neuroendocrine tumors: A review of serum biomarkers, staging, and management.

Authors:  Zu-Yi Ma; Yuan-Feng Gong; Hong-Kai Zhuang; Zi-Xuan Zhou; Shan-Zhou Huang; Yi-Ping Zou; Bo-Wen Huang; Zhong-Hai Sun; Chuan-Zhao Zhang; Yun-Qiang Tang; Bao-Hua Hou
Journal:  World J Gastroenterol       Date:  2020-05-21       Impact factor: 5.742

Review 3.  Unraveling tumor grading and genomic landscape in lung neuroendocrine tumors.

Authors:  Giuseppe Pelosi; Mauro Papotti; Guido Rindi; Aldo Scarpa
Journal:  Endocr Pathol       Date:  2014-06       Impact factor: 3.943

4.  Everolimus in the treatment of neuroendocrine tumors: efficacy, side-effects, resistance, and factors affecting its place in the treatment sequence.

Authors:  Lingaku Lee; Tetsuhide Ito; Robert T Jensen
Journal:  Expert Opin Pharmacother       Date:  2018-05-24       Impact factor: 3.889

Review 5.  Neuroendocrine tumors of the pancreas: current concepts and controversies.

Authors:  Michelle D Reid; Serdar Balci; Burcu Saka; N Volkan Adsay
Journal:  Endocr Pathol       Date:  2014-03       Impact factor: 3.943

Review 6.  Update on pancreatic neuroendocrine tumors.

Authors:  Logan R McKenna; Barish H Edil
Journal:  Gland Surg       Date:  2014-11

7.  Grading of EUS-FNA cytologic specimens from patients with pancreatic neuroendocrine neoplasms: it is time move to tissue core biopsy?

Authors:  Rakesh Vinayek; Gabriele Capurso; Alberto Larghi
Journal:  Gland Surg       Date:  2014-11

8.  Revised staging classification improves outcome prediction for small intestinal neuroendocrine tumors.

Authors:  Michelle Kang Kim; Richard R P Warner; Sasan Roayaie; Noam Harpaz; Stephen C Ward; Steven Itzkowitz; Juan P Wisnivesky
Journal:  J Clin Oncol       Date:  2013-09-16       Impact factor: 44.544

9.  Analysis of 100 consecutive cases of resectable pancreatic neuroendocrine neoplasms: clinicopathological characteristics and long-term outcomes.

Authors:  Yugang Cheng; Hanxiang Zhan; Lei Wang; Jianwei Xu; Guangyong Zhang; Zongli Zhang; Sanyuan Hu
Journal:  Front Med       Date:  2016-12-23       Impact factor: 4.592

10.  Ki-67 cytological index can distinguish well-differentiated from poorly differentiated pancreatic neuroendocrine tumors: a comparative cytohistological study of 53 cases.

Authors:  Gabriele Carlinfante; Paola Baccarini; Debora Berretti; Tiziana Cassetti; Maurizio Cavina; Rita Conigliaro; Alessandro De Pellegrin; Luca Di Tommaso; Carlo Fabbri; Adele Fornelli; Andrea Frasoldati; Giorgio Gardini; Luisa Losi; Livia Maccio; Raffaele Manta; Nico Pagano; Romano Sassatelli; Silvia Serra; Lorenzo Camellini
Journal:  Virchows Arch       Date:  2014-05-08       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.